In this revised A1 application for competitive renewal, we will focus on the impact of HIV-1 replicative fitness as it relates to transmission efficiency and subsequent disease progression. Based on our ten year Uganda/Zimbabwe (Ug/Zim) natural HIV-1 history cohort study involving 270 women (>10,000 data/sample points), CD4 cell declines in subtype C infected women were significantly slower than in subtype A and subtype D infected women.
In aim 1, we will continue our analyses of HIV-1 fitness in this cohort and will determine if the pathogenic fitness of the HIV-1 establishing acute/early infection predicts subsequent disease progression based on viral loads and CD4 cell counts. The transmitted/founder (TF) HIV-1 from the blood of ~200 patients will be used in multiple competitions that can now be rapidly analyzed with a new 454 approach and sophisticated algorithms. We now show that slow disease progression is associated with infection by a less fit HIV-1 isolate, generally subtype C whereas subtype D TF HIV-1 isolates have the highest replicative fitness and causes the fastest disease progression. Subtype C may have expanded in HIV pandemic based increased opportunity for transmission (longer disease progression) but relative transmission efficiency between subtypes is the other half of the R0 equation.
In aim 2, we will perform infections/competitions using various human mucosal tissue (penile, cervical, and rectal) with a mixture of 5-10 viruses derived from acute/early infection to determine transmission fitness in an ex vivo model. Based on preliminary data, the subtype C TF HIV-1 had higher transmission fitness than subtype A and D TF HIV-1 in the penile and cervical tissue. We also have preliminary data suggesting that HET TF HIV-1 may have different phenotypic properties than subtype B TF HIV-1 derived from men-who-have-sex- with-men (MSM), IV drug users (IVDU), or hemophiliacs (HEMO).
In aim 2, we will determine if HET subtype B TF HIV-1 have slightly higher transmission fitness in cervical and penile tissue models than MSM TF HIV-1 or than IVDU/HEMO TF HIV-1. We propose that the penile, cervical, and vaginal mucosa will select for distinct phenotypic properties (aim 3) in the TF HIV-1 from HET and MSM transmission due to a more significant barrier than found in rectal tissue or blood. In specific ai 3, we will the mechanisms controlling pathogenic and transmission fitness. We propose that this """"""""pathogenic"""""""" fitness in PBMCs, T cells, and macrophages is directly related to the efficiency of host cell entry considering that more fit primary HIV-1 isolates have faster entry kinetics, greate ability to infect cells of low CD4/low CCR5 (Affinofile), and are typically less sensitive to entry inhibitors (aim 3). Based on preliminary data, transmission fitness may be more dependent on higher CD4 affinity, reduced levels of N linked glycosylation on the virus envelope, and reduced lectin binding affinity. We propose that the majority of HIV-1 transmitted from donor to recipient is trapped in the mucosal tissue (e.g. cervix) due to lectin binding and other barriers that effectively """"""""keep pathogens out"""""""".

Public Health Relevance

HIV is not a single virus infecting 33 million people worldwide but rather, 33 million different viruses infecting 33 million people. This virus has evolved at an alarming rate since entering the human population near the turn of 19th century. Aside from being different in its genetic code, different HIV-1 subtypes and recombinant forms may not have evolved to the same virulence;that is some types of HIV-1 may cause a faster progression to AIDS than others. In this grant proposal, we now suggest that stage is set for the aggressive nature of disease based on what type of HIV-1 strain found at the earliest time within the blood of the newly infected person. In addition, by comparing the rate of disease progression in Ugandan and Zimbabwean over the past ten years, we show that infection with HIV-1 subtype C (predominant in the world) causes slower disease as compared to HIV-1 subtype A and D infections (also highly prevalent in Africa). Although this difference requires years of study in patients, we now know that the HIV-1 subtype C strains in laboratory experiments is much less fit than the HIV-1 subtype A and D strains. These studies suggest we may have a surrogate laboratory assay that predicts a 10 year disease course and also provides a time estimate as to when to begin treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI049170-10A1
Application #
8609136
Study Section
AIDS Molecular and Cellular Biology Study Section (AMCB)
Program Officer
Sanders, Brigitte E
Project Start
2000-12-01
Project End
2017-07-31
Budget Start
2013-08-05
Budget End
2014-07-31
Support Year
10
Fiscal Year
2013
Total Cost
$449,769
Indirect Cost
$146,021
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Pankrac, Joshua; Klein, Katja; McKay, Paul F et al. (2018) A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. NPJ Vaccines 3:2
Klein, Katja; Nickel, Gabrielle; Nankya, Immaculate et al. (2018) Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection. PLoS Pathog 14:e1006754
Bagaya, Bernard S; Tian, Meijuan; Nickel, Gabrielle C et al. (2017) An in vitro Model to Mimic Selection of Replication-Competent HIV-1 Intersubtype Recombination in Dual or Superinfected Patients. J Mol Biol 429:2246-2264
Gibson, Richard M; Nickel, Gabrielle; Crawford, Michael et al. (2017) Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries. Infect Dis Poverty 6:163
Asmal, Mohammed; Lane, Sophie; Tian, Meijuan et al. (2016) Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections. Virology 499:298-312
Choi, Eunsil; Michalski, Chad J; Choo, Seung Ho et al. (2016) First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. Retrovirology 13:82
Tebit, Denis M; Patel, Hamish; Ratcliff, Annette et al. (2016) HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs. AIDS Res Hum Retroviruses 32:676-88
Johnson, Aaron L; Dirk, Brennan S; Coutu, Mathieu et al. (2016) A Highly Conserved Residue in HIV-1 Nef Alpha Helix 2 Modulates Protein Expression. mSphere 1:
Krebs, Kendall C; Tian, Meijuan; Asmal, Mohammed et al. (2016) Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. AIDS Res Ther 13:41
Venner, Colin M; Nankya, Immaculate; Kyeyune, Fred et al. (2016) Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa. EBioMedicine 13:305-314

Showing the most recent 10 out of 44 publications